<DOC>
	<DOCNO>NCT01299857</DOCNO>
	<brief_summary>The purpose study study midterm clinical evaluation , biological parameter immune reconstitution Rituximab treatment Pemphigus .</brief_summary>
	<brief_title>Long-term Clinical Biological Evaluation Patients With Severe Forms Pemphigus Treated Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>age &gt; 18 consentment patient treat Rituximab include clinical trial n°2002/020/HP NCT00213512 `` Treatment Patients Presenting Pemphigus With Anti CD20 ( Mabthera ) '' . age &lt; 18 consentment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>pemphigus</keyword>
	<keyword>Mabthéra ( R )</keyword>
	<keyword>B lymphocyte</keyword>
	<keyword>desmogleines</keyword>
</DOC>